Opus Genetics, Inc. announced the dosing of the first pediatric patient in its Phase 1/2 trial for OPGx-LCA5, a gene therapy targeting Leber congenital amaurosis (LCA). Initial results from this ...

The ACTIVATE-Kids and ACTIVATE-KidsT Phase 3 studies mark Agios’ first pediatric clinical program for a rare hemolytic anemia, providing valuable insights that will help shape the company’s ...

About the CIDS Phase III The CIDS Phase III was a multicenter, multinational, randomized, controlled, open label study, conducted in pediatric patients with deep partial thickness (DPT ...

Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.

An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned ...

MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

Findings in Burns Journal confirm NexoBrid’s superiority over standard of care in pediatric patients with deep thermal ...